As the Dutch government gets more aggressive about controlling the cost of medicines, the pharmaceutical industry is firing back by arguing the business climate is “under pressure” and questioning policies that are “increasingly undermining” the ability to develop and market new drugs.
The statement from the pharmaceutical committee of the American Chamber of Commerce in the Netherlands follows remarks by Bruno Bruins, the minister for medical care, who wants prices justified, has expressed interest in compulsory licensing, suggested reviewing market exclusivity for orphan drugs, and supports “magisterial preparation,” which allows pharmacists to make competitive treatments.
About the Author Reprints
